Proactive Investors - Run By Investors For Investors

Risers & Fallers: Centamin, Conroy Gold, DP Poland, Essenden, Premaitha, Tavistock


The following are some of the major news-driven share price changes as at 1.30pm.


Premaitha Health (LON:NIPT), up 35.6%. The non-invasive pre-natal test (NIPT) specialist has been chosen by the St George’s University Hospitals NHS Foundation Trust to provide its IONA test product over a three-year period, with the option to roll-over the contract annually.

Centamin (LON:CEY), up 15.7%. Full-year results gave the shares a boost. Output in 2014 was up 6% at 377,261 ounces of gold; 128,115 ounces were produced in the final quarter. This year production is expected to grow to 420,000 at a cash cost of U$700 an ounce or an all in sustaining cash cost of US$950 an ounce.

Essenden (LON:ESS), up 14.6%. The company said on Friday it has received a preliminary bid approach from a private equity firm. The bowling alley operator said in its results statement on 12 March that it has now reached a point where it is appropriate to examine a range of strategic options that could further enhance shareholder value given recent and potential corporate activity in the bowling sector.


Tavistock Investments (LON:TAVI), down 7.9%. Interim results from the financial services group failed to impress. Loss before tax widened to £343,000 from £246,000 the year before.

DP Poland (LON:DPP), down 6.3%. Underlying losses before exceptional items in 2014 narrowed to £2.41mln from £2.84mln in 2013, with the company putting in a strong finish to the year, with EBITDA for the retail estate positive in each of the final three months of the year.

Conroy Gold & Natural Resources (LON:CGNR), down 6.3%. In-fill drilling at its Clontibret asset in Ireland encountered high grade gold, with grades of 25.29 grams per tonne (g/t) over one 2.5 metre span, and 22.37 g/t over a one metre stretch elsewhere.


Following are some of the major news-driven price changes as at 11.15am.


Immedia (LON:IME), up 21.2%. The shares advanced 3.5p to 20p after a bit of share shuffling by members of the Horrocks family.

Metal Tiger (LON:MTR), up 20.8%. The natural resources investment firm is now able to self-finance its activities, it told investors.

Silence Therapeutics (LON:SLN), up 17.9%. The company’s lead drug candidate has shown early signs of efficacy when used in combination with traditional chemotherapy to treat people with terminal pancreatic cancer.


Karelian Diamond Resources (LON:KDR), down 16.4%. Investors banking profits after Friday’s stonking rise, which was sparked by the discovery of a potential new diamond source in Finland.

Europa Oil & Gas (LON:EOG), down 11.9%. The Kiln Lane-1 well on licence PEDL 181 in north-east Lincolnshire, has been plugged and abandoned. Europa is operator of, and has a 50% working interest in, PEDL 181, which covers an area of over 540 square kilometres in the East Midlands Petroleum Province. Egdon Resources and Celtique Energie Petroleum each have a 25% interest in the licence.

ScS Group (LON:SCS), down 9.7%. Furniture and floorings seller disappointed with its first set of results since listing at the end of January. It made an underlying loss of £3.0mln in the 26 weeks to 24 January, versus a loss of £1.3mln a year earlier. The firm cushioned the blow by revealing sales order intake was up 7.5% on a like-for-like basis for the first 33 weeks of the financial year.


Below are some of the major new-driven share price changes as at 9.00am.


Helius Energy (LON:HEGY), up 115.4%. The company announced after the close of trading on Friday that it plans to get shot of its CoRDe business for £12.3mln, delist from AIM and return cash to shareholders.

Challenger Acquisitions (LON:CHAL), up 21.2%. Speculators are still getting on board after the recently-listed investment company announced a co-operation deal last week with Starneth, the firm behind the London Eye. The market value of the company was just £1.1mln when it floated on 19 February; it is now worth £5.1mln.

Verona Pharma (LON:VRP), up 19.6%. Interim results from the respiratory disease specialist’s new RPL554 trial demonstrate excellent drug tolerability even at the highest dose, the company revealed.


Clean Air Power (LON:CAP), down 22.0%. Full-year loss deepened to £6.34mln from £2.00mln in 2013, while revenue fell to £6.76mln from £9.93mln. On the bright side, the dual-fuel engine management software developer has been awarded an additional one year extension to its two-year funded research project with Brunel University London, aimed at developing the next generation of advanced dual-fuel combustion systems.

Spaceandpeople (LON:SAL), down 17.9%. Profits on 2014 slumped to £1.0mln from £2.6mln, and the full-year dividend has been more than halved to 2.0p from 4.1p.

Egdon Resources (LON:EDR), down 15.2%. Drilling at the Kiln Lane-1 exploration well, in which Egdon has a 25% interest, has not produced the results hoped for, and the well has been plugged and abandoned.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use